Ovarian hyperstimulation syndrome (OHSS) diagnostic marker Kallistatin and application thereof

A syndrome and ovarian technology, applied in the fields of biotechnology and medical testing, can solve problems such as insufficient ovarian hyperstimulation syndrome, and achieve the effect of enriching clinical detection methods, good sensitivity and specificity

Active Publication Date: 2020-08-18
GUANGDONG NO 2 PROVINCIAL PEOPLES HOSPITAL
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition to ultrasound technology, most of the existing technologies use its clinical manifestations and basic information to support the disease, and there is no sufficient evidence and disease mechanism to support the occurrence of ovarian hyperstimulation syndrome.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ovarian hyperstimulation syndrome (OHSS) diagnostic marker Kallistatin and application thereof
  • Ovarian hyperstimulation syndrome (OHSS) diagnostic marker Kallistatin and application thereof
  • Ovarian hyperstimulation syndrome (OHSS) diagnostic marker Kallistatin and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1 Kallistatin protein is widely expressed in ovarian granulosa cells

[0032] This example detects the expression of Kallistatin protein in the granulosa cell line KGN and primary ovarian granulosa cells.

[0033]1. Expression of Kallistatin in granulosa cell line KGN cells

[0034] The granulosa cell line KGN cells were cultured, and the expression of Kallistatin factor in the cells was detected by immunofluorescence.

[0035] (1) Culture of KGN cells

[0036] Take DMEM / F12 medium, add FBS (10%) and penicillin / streptomycin double antibody (1%) to prepare cell culture medium, culture cells in 100mm cell culture dish, change medium every other day, until cell density reaches 80% Cells were subcultured when left or right.

[0037] (2) Cell immunofluorescence detection

[0038] 1) Digest and centrifuge cells with a fusion degree of about 70%, resuspend with 3ml of cell culture medium, add about 250ul of cell suspension into a laser confocal small dish, then add...

Embodiment 2

[0063] Example 2 Expression of Kallistatin protein in clinical samples of patients at high risk of OHSS and the control group undergoing assisted reproduction

[0064] This example studies the expression of Kallistatin protein in the follicular fluid and serum of the OHSS high-risk group and the control group undergoing assisted reproduction.

[0065] On the basis of the informed consent of the patients and the approval of the hospital ethics committee, in vitro fertilization / intracytoplasmic sperm injection-embryo transfer (IVF) was selected in the Reproductive Center of the Third Affiliated Hospital of Guangzhou Medical University from March 2016 to August 2016. / ICSI-ET) assisted infertility female patients, collect follicular fluid and / or blood samples on the day of egg retrieval, and / or extract granulosa cells from follicular fluid for experiments. The patients were divided into two groups according to their general characteristics such as age, body mass index (BMI), infe...

Embodiment 3

[0104] Example 3 Expression of Kallistatin gene in clinical samples of high-risk OHSS and control group patients undergoing assisted reproduction

[0105] This example studies the expression of the Kallistatin gene in the follicular fluid of the OHSS high-risk group and the control group undergoing assisted reproduction.

[0106] 1. RNA extraction: extract the total RNA in the follicular fluid of patients with high risk of OHSS and the control group undergoing assisted reproduction. Collect an appropriate amount of follicular fluid from the patient on the day of egg retrieval, centrifuge at 1500-1800rpm at 4°C for 15min, pipette 1ml of the supernatant into two 2mlEP tubes, and mark the patient’s name, group and other information on the tube wall. Store in -80°C freezer. Add an appropriate amount of Trizol, blow and beat repeatedly to lyse the cells, and then transfer to an RNase-free EP tube; if it is a tissue, use a mortar to grind the tissue, then add an appropriate amount ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention discloses an ovarian hyperstimulation syndrome (OHSS) detection marker Kallistatin, and also discloses an application of Kallistatin protein in screening and / or preparation of an ovarianhyperstimulation syndrome detection reagent, and the ovarian hyperstimulation syndrome detection kit. Through research, the inventor of the invention finds that Kallistatin is widely expressed in ovarian granular cells, and the expression level in cell nucleuses is higher than that in cytoplasm. The inventor finds for the first time that compared with a control group for assisted reproduction, inclinical follicular fluid specimens and serum specimens of an OHSS high-risk group, the expression of Kallistatin protein is obviously reduced; compared with a normal pregnant woman, the content of Kallistatin in serum of an OHSS patient is remarkably reduced. It is prompted that Kallistatin can be used as a specific detection marker of OHSS, is used for screening and preparing an OHSS detectionkit, and has good sensitivity and specificity. The invention provides a novel specific molecular marker for clinical detection of OHSS, and enriches the clinical detection method of OHSS.

Description

technical field [0001] The invention belongs to the technical field of biotechnology and medical detection, and in particular relates to Kallistatin, a diagnostic marker for ovarian hyperstimulation syndrome, and its application. Background technique [0002] Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic disease related to assisted reproductive technology and the main complication of controlled hyperovulation. It can threaten the life of patients in severe cases and should be actively prevented and treated. OHSS is characterized by the development of multiple follicles in both ovaries, ovarian enlargement, abnormal capillary permeability, abnormal body fluid and protein extravasation into the third space of the human body, and then causes a series of clinical symptoms. It usually occurs in the first trimester after the HCG trigger or after transplantation. Clinically, OHSS often manifests as nausea, vomiting, abdominal distension, oliguria, weight gain, and dysp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68C12Q1/6883
CPCC12Q1/6883C12Q2600/158G01N33/6893G01N2333/8121G01N2800/36
Inventor 姚亚超李磊易婧雅刘静曹东林
Owner GUANGDONG NO 2 PROVINCIAL PEOPLES HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap